In a preliminary test, anticancer drugs including cisplatin, doxorubicin, and MK-2206 were combined with WZB117, and the allosteric Akt inhibitor MK-2206 showed the best synergistic anticancer effect with WZB117 in breast cancer cells (Supplementary Figure S1). Here, AKT1 is linked to breast cancer.